Figure S2


2202 Screened
1689 Excluded
513 Randomized (2:1)
339 assigned to veliparib + C/P
174 assigned to placebo + C/P
336 received treatment and were included in safety analyses
337 had suspected deleterious/deleterious *BRCA1/2* mutation by core lab and were included in efficacy analyses (ITT)
171 received treatment and were included in safety analyses
172 had suspected deleterious/deleterious *BRCA1/2* mutation by core lab and were included in efficacy analyses (ITT)
334 patients in the ITT population received treatment
170 patients in the ITT population received treatment
267 discontinued study drug[a]
• 192 progressive disease per protocol
• 32 adverse event not related to progression
• 23 adverse event related to progression
• 20 withdrew consent
• 20 discontinued for other reasons
• 5 completed treatment
• 2 were lost to follow-up
153 discontinued study drug[a]
• 121 progressive disease per protocol[b]
• 9 adverse event not related to progression
• 9 adverse event related to progression
• 9 withdrew consent
• 14 discontinued for other reasons
• 1 completed treatment
• 2 were lost to follow-up
75 received open-label veliparib monotherapy after progression
• 28 had ctDNA evaluable for *BRCA* reversion mutations
67 patients on study treatment at the data cutoff
17 patients on study treatment at the data cutoff